Effects of thiazolidinediones on bone loss and fracture

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 2014-2018

  Murphy, Catherine E ^a   Rodgers, Philip T ^a,b,c  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Fracture; Peroxisome proliferator activated receptor ; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; FRACTURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; SIDE EFFECT;

ANIMALS; BONE AND BONES; BONE DENSITY; DIABETES MELLITUS; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 36849062521     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K286     Document Type: Article

References (27)

1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
2. DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105.
3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
4. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Circulation 2003;108:2941-8.
5. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-35.
6. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernick B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6.
7. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-8.
8. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 2001;276:16767-71.
9. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148:2669-80.
10. Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-16.
11. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004;75:329-37.
12. Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001;69:46-50.
13. Clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia (rosiglitazone maleate) tablets for type 2 diabetes mellitus. Dear Healthcare Provider Memo. www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf (accessed 2007 May 17).
14. Observation of an increased incidence of fractures in female patients who received long-term treatment with Actos (pioglitazone HCl) tablets for type 2 diabetes mellitus. Dear Healthcare Provider Memo. www.fda.gov/medwatch/safety/ 2007/Actosmar0807.pdf (accessed 2007 May 17).
15. Kahn S, on behalf of the ADOPT investigators. Increased incidence of fractures in women who received rosiglitazone in ADOPT. American Diabetes Association 2007 Scientific Sessions; June 26, 2007; Chicago, IL.
16. Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999;46:195-201.
17. Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 2003;21:166-71.
18. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54.
19. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10.
20. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007;30:1574-6.
21. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003;32:83-113.
22. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.
23. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.
24. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-8.
25. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults. Arch Intern Med 2005;165:1612-7.
26. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997;82:2915-20.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.